COMMUNIQUÉS West-GlobeNewswire
-
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
30/06/2026 -
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
30/06/2026 -
Les échafaudages régénératifs de BellaSeno annoncent l’avènement d’une nouvelle ère pour la chirurgie mammaire
30/06/2026 -
Jushi Celebrates Enactment of Virginia Adult-Use Cannabis Legislation
30/06/2026 -
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
30/06/2026 -
Commure Launches Orchestrator: The AI-Native Referral Management and Patient Intake Platform
30/06/2026 -
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
30/06/2026 -
FEATOL Rolls Out Reinforced Lower Back Brace to Help Adults During Work, Driving, and in Chronic Pain
30/06/2026 -
Transactions in connection with share buy-back program
30/06/2026 -
Salipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteins
30/06/2026 -
Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners
30/06/2026 -
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
30/06/2026 -
HUTCHMED to Announce 2026 Half-Year Financial Results
30/06/2026 -
smartbax secures additional financing to advance lead antibiotic program to IND filing
30/06/2026 -
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
30/06/2026 -
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
30/06/2026 -
The National Proton Therapy Center of Portugal will be equipped with two IBA Proteus®ONE solutions
30/06/2026 -
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
30/06/2026 -
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
30/06/2026
Pages